Enoxaparin sodium
- PDF / 178,999 Bytes
- 2 Pages / 595.245 x 841.846 pts (A4) Page_size
- 30 Downloads / 186 Views
1 S
Thrombocytopenia: 9 case reports In a single-center observational study consisting of women, whose pregnancy data was recorded from May 2009 and January 2020, nine women [ages not stated] were described, who developed thrombocytopenia following treatment with enoxaparin sodium for prevention of thromboembolic complications during pregnancy [not all routes, dosages and neonate gender stated; time to reaction onsets and outcomes not stated]. Patient 1 from table 1 of the article: A woman had been diagnosed with de novo paroxysmal nocturnal hemoglobinuria (PNH) and haemolytic anaemia. Her first two pregnancies had been complicated by haemolysis secondary to PNH. She had been treated with eculizumab for PNH and haemolytic anaemia during her first two pregnancy. She conceived her third pregnancy 96 months after the diagnosis of de novo PNH. During the third pregnancy, she started receiving SC enoxaparin sodium [enoxaparin] for prevention of thromboembolic complications. She also received concomitant eculizumab 900mg infusion every two weeks since prior to the current pregnancy. During the pregnancy, she experienced breakthrough haemolysis. Therefore, eculizumab dose was increased to 1200mg every two weeks and later to 1800mg every two weeks. She developed thrombocytopenia secondary to enoxaparin sodium. She also received red blood cell transfusion. At the gestational age of 38 weeks and 5 days, she delivered a neonate through vaginal delivery. The neonate weighed 3870g with height of 53cm, head circumference of 36cm and Apgar score of 9/10/10. Enoxaparin sodium therapy was continued during and upto six months after the pregnancy. Eculizumab therapy was also continued at a dose of 1200mg every two weeks after pregnancy. Patient 2 from table 1 of the article: A woman was diagnosed with de novo paroxysmal nocturnal hemoglobinuria (PNH) and haemolytic anaemia. She conceived her first pregnancy 63 months after the PNH diagnosis. She started receiving SC enoxaparin sodium [enoxaparin] for prevention of thromboembolic complications. She also received unspecified glucocorticoids and transfusions. During the pregnancy, she developed breakthrough haemolysis, Budd-Chiari syndrome and cholecystitis. She started receiving eculizumab infusion at a dose of 900mg weekly which was later changed to 1800mg. She also received unspecified anticoagulation and antibiotics. She developed thrombocytopenia secondary to enoxaparin sodium. She was treated with red blood cell and platelet transfusion. At the gestational age of 35 weeks and 3 days, she delivered a neonate through cesarean section. The neonate weighed 2380g with height of 46cm, head circumference of 32cm and Apgar score of 9/10/10. Enoxaparin sodium therapy was continued during and upto six months after the pregnancy. Eculizumab therapy was also continued at a dose of 900mg every two weeks after pregnancy. Patient 3 from table 1 of the article: A woman was diagnosed with non-severe aplastic anaemia-paroxysmal nocturnal hemoglobinuria (PNH), haemolytic anaemia, Budd-Chiari syndro
Data Loading...
